Mounjaro doses explained: what the titration schedule actually means for you

Where the dose schedule comes from — and why it starts low

The titration ladder in Mounjaro's UK licence is not arbitrary. It was designed around the trial programme that underpinned NICE's recommendation of tirzepatide, published as TA1026 in December 2024, and reflects a straightforward clinical logic: the same mechanism that reduces appetite and slows gastric emptying can also trigger nausea and digestive discomfort, especially early on. Starting at 2.5 mg gives the gut time to adjust. The dose isn't expected to drive significant weight loss at that stage, and that's by design.

Each step up (from 2.5 to 5 mg, then 7.5, 10, 12.5 and finally 15 mg) is held for roughly four weeks before reassessment, and if you want a clear breakdown of what each strength is intended to achieve, the Mounjaro doses page walks through the full titration schedule in detail. A prescriber may recommend staying at a given dose for longer if side effects are still settling, or if a patient is managing well and there's no clinical reason to push higher. The ceiling isn't a target. Some people plateau at 10 mg with excellent results and no reason to continue climbing.

One misconception that comes up frequently: people assume that a higher dose is always better, or that stopping short of 15 mg means the treatment isn't working. The evidence doesn't support that. The therapeutic aim is the lowest dose that achieves meaningful, tolerable results for that individual.

What the trial data actually shows at different doses

SURMOUNT-1, the pivotal phase 3 trial, compared three doses over 72 weeks in adults with obesity who did not have type 2 diabetes. Weight loss was dose-dependent: participants on 5 mg lost an average of around 15% of body weight, those on 10 mg around 19.5%, and those on 15 mg around 20.9%. These are group averages; individual results varied considerably. You can explore the broader Mounjaro overview for more context on how the medicine works as a dual GIP and GLP-1 receptor agonist.

The implication of that dose-response curve is real but more nuanced than headlines suggest. The jump from 10 mg to 15 mg added roughly 1–1.5 percentage points of average loss, meaningful in a clinical programme, but not the kind of difference that makes 15 mg the automatic answer for everyone. For people who reach a good outcome at 10 mg and tolerate it well, there may be little to gain and more to manage at a higher dose. That is exactly the kind of individual calculation a prescriber is there to make.

If you're wondering how the pen itself is structured (how many doses are contained in a single KwikPen and how they're delivered) the Mounjaro KwikPen doses page covers that in detail.

Side effects along the titration route, and what to watch for

The gastrointestinal side effects (nausea, loose stools, constipation, indigestion, burping) tend to be most noticeable at the start of treatment or after a dose increase. For most people they settle within days to two weeks as the body adapts. The titration schedule is partly designed with this in mind: moving slowly enough that the gut can keep pace.

More serious symptoms warrant prompt medical attention. Severe stomach pain that reaches through to the back, with or without vomiting, can be a sign of pancreatitis, a rare but known risk with GLP-1 medicines. The MHRA Yellow Card scheme allows patients to report suspected side effects directly, and doing so helps the regulator monitor real-world safety. Patients can also report via their prescriber or pharmacist.

Other things prescribers monitor include injection-site reactions, gallbladder symptoms, and signs of dehydration if nausea or diarrhoea is prolonged. The Patient Information Leaflet supplied with every pen is the authoritative reference for the full side-effect profile and what action to take, not a summary on a website.

Practical questions about doses: volume, single-pen structure and what comes next

Each Mounjaro KwikPen is pre-filled and delivers four weekly doses. The volume delivered per injection is small and fixed by the device; you don't measure or draw anything. If you're curious about the actual volume in millilitres per dose, the doses in ml page explains how this is expressed on the SmPC. For those asking about single-dose pens at a specific strength, the single-dose pen page covers what's available in the UK.

Storage matters throughout the programme. Pens must be kept refrigerated at 2–8°C; there is a limited window during which a pen can be kept at room temperature before use, and the exact figure lives in the SmPC rather than here, your prescriber or the leaflet is the right place to check. Injection sites rotate between the abdomen, thigh and upper arm to avoid localised reactions.

Questions about cost often arise when people are planning several months of treatment across multiple dose steps. The cost context page covers what UK private prices typically include and what to watch for. The clinical question (the right dose for you) is answered through assessment, not price.

If you're at a point where a clinical review feels like the right next step, you can check your eligibility through a free consultation with one of our GPhC-registered prescribers. The assessment is the same day and carried out by a real clinician, not automated software.